Resumen

ZAZUETA-POZOS, Juan F. et al. Lymphoma and COVID-19. Gac. Méd. Méx [online]. 2021, vol.157, suppl.3, pp.S35-S41.  Epub 25-Abr-2022. ISSN 2696-1288.  https://doi.org/10.24875/gmm.m21000468.

The SARS-CoV-2 virus and its clinical translation COVID-19 represent a disease with potentially fatal respiratory manifestations. Currently, there are approximately 12,700,000 people affected by this virus, which has caused 561,517 deaths worldwide. Patients with a diagnosis of lymphoma, like other patients with active cancer, have immune compromise either due to their own pathology or due to the treatment they receive, making them especially susceptible to developing severe cases of COVID-19. The community transmission of SARS-CoV-2 hinders access to the health system and, therefore, the strict monitoring required by patients undergoing cancer treatment. At the stage we are currently in, global transmission of SARS-CoV-2 infection continues to rise, making close epidemiological control unlikely. In this context, the need arises to establish guidelines for the treatment of patients with hematological malignancies.

Palabras llave : Non-Hodgkin lymphoma; Diffuse large B cell lymphoma; Mantle cell lymphoma; Follicular lymphoma; SARS-CoV-2; Coronavirus.